Previous studies have reported that the downstream activation of the type I interferon or NF‐κB pathways by cGAS–STING can upregulate PD‐L1 expression.[23] However, when myeloma cells were co‐treated with the NF‐κB inhibitor bortezomib and STAT pathway inhibitor nifuroxazide, the chemotherapeutic drugs still upregulated PD‐L1 expression, indicating that IRF7 may have alternative regulatory pathways for upregulating PD‐L1 expression (Figure S6A,B, Supporting Information). Here, IRF7 is linked to plasma cell myeloma.